Loading…
← CockpitCompetitor Analysis › 458870.KS SEERS Co. Ltd.Open in the cockpit ↗

SEERS Co. Ltd.458870.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical Specialties
Momentum laggard 1
Mkt cap
$392M
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$7.79M
20-day average traded
Fwd P/E
15.2×
forward earnings
ROIC−WACC
+41.0 pp
WACC 5.6%
Hurdle
-253 pp
Req g minus delivered
Next earnings
121 days
19 Mar 2027
Close · KRW₩12,380
1D-3.7%
1W-14.7%
1M-45.7%
3M-48.3%
6M-69.7%
YTD-71.5%
1Y-57.2%
ATR %14.9%
52w lowhigh80.7% off high

What SEERS does

Employees: 130

SEERS at a glance

Size SEERS (458870.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $392M, the 406th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩12,380 on 18 Nov 2026.

Performance Over six months the shares fell 69.7%, against -18.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue grew 174.0% over the last twelve months (peer median +13.9%); the operating margin is 36.6% (peer median 4.2%).

Valuation It trades at 15.2× forward earnings against a peer median of 18.2× (4th cheapest of 10).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +247%, so the hurdle is -253 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 41.0 points above its cost of capital (5.6% WACC).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510021 May 202621 Aug 202618 Nov 2026Peer median 83458870.KS 34
Six months, rebased to 100: SEERS against the median of its 20 peers (local-currency closes).

SEERS financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩91.1B₩48.2B₩8.10B₩1.89B₩1.15B
Revenue growth—+495%+330%+63%—
Gross profit₩60.7B₩34.2B₩2.86B-₩1.30B-₩829M
EBITDA₩35.1B₩17.6B-₩7.56B-₩8.81B-₩7.48B
Net income₩33.3B₩16.1B-₩8.87B-₩9.92B-₩7.99B
Free cash flow₩10.9B₩610M-₩11.5B-₩8.58B-₩17.3B
Capital expenditure₩3.40B₩2.13B₩1.41B₩1.11B₩8.91B
Total debt₩5.11B₩3.81B₩3.05B₩6.29B₩1.72B

Quarterly statements and history in the cockpit →

SEERS competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%+20%CERS6929002022MASS47363002380418306748BWAY9877301097CVSBS1609458870.KS6-month return →1-month return →
Up and to the right = strong over both horizons. SEERS is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%10×20×30×6929688133041830605186688358300562BWAYSBS688338458870.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SEERS is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%6929MASS47366883582041BWAY1609458870.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. SEERS is the large dot.

SEERS competitors and peer comparison

How SEERS compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SEERS against its 20 peers (data as of 18 Nov 2026)
Measure458870.KSPeer medianRank in peer set
1-month return-45.7%-10.9%lowest of 21
6-month return-69.7%-18.1%2nd lowest of 20
Distance from 52-week high-80.7%-44.7%2nd lowest of 21
Revenue growth (TTM)+174.0%+13.9%2nd highest of 21
Operating margin36.6%4.2%2nd highest of 21
Forward P/E15.2×18.2×4th cheapest of 10
Growth the price implies (Req g, 7 yrs)-6.3%5.7%5th least demanding of 12
Growth delivered (Del g)+247.0%+15.4%highest of 12
Hurdle (Req g minus delivered)-253.3 pp+1.8 ppleast demanding of 12
ROIC minus cost of capital+41.0 pp-2.1 pp2nd highest of 20
EV / EBITDA14.3×8.5×4th most expensive of 9
Net debt / EBITDA-0.4×-2.8×3rd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
SEERS 458870.KSSouth Korea$392M-70%+174%37%15.2×-6.3%+247.0%
Cerus CERSUnited States$392M-28%+14%-12%n/an/an/a
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%8.4×-17.6%+15.4%
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%n/an/an/a
908 Devices MASSUnited States$396M+36%+14%-33%n/a41.7%+15.9%
Taidoc Technology 4736.TWTaiwan$387M0%0%19%n/a-9.5%-6.6%
Guanhao Biotech 300238.SZChina$397M-26%-12%3%n/an/an/a
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%8.4×n/an/a
InBody 041830.KSSouth Korea$380M-13%+22%22%11.3×-10.3%+16.9%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%37.2×n/an/a
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%19.8×9.6%+5.6%
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%n/a17.1%+18.1%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%n/an/an/a
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%25.3×-4.2%-6.0%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%20.3×24.9%+18.8%
Jenscare Scientific 9877.HKHong Kong$415M-32%+993%-106%n/an/an/a
Ningbo Tianyi Medical Appliance 301097.SZChina$418M-22%+46%8%n/an/an/a
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%16.4×5.7%+3.4%

Questions

Which companies are SEERS's closest peers?
The cockpit's peer set: Cerus (CERS), OrbusNeich Medical (6929.HK), Shanghai Kehua Bio-Engineering (002022.SZ), 908 Devices (MASS), Taidoc Technology (4736.TW), Guanhao Biotech (300238.SZ), Shanghai Titan Scientific (688133.SS), InBody (041830.KS).
Is SEERS expensive compared with its peers?
On forward p/e it trades at 15.2× against a peer median of 18.2×, 4th cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +247%, so the hurdle is -253 pp: the price already allows for a slowdown.
How has SEERS stock performed?
Over six months to 18 Nov 2026 the shares returned -69.7% against -18.1% for the median peer; over one year -57.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.